Zydus Cadila has received the final approval from the USFDA to market Itraconazole Capsules 100 mg. The drug is used to treat a variety of fungal infections and will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.

The group now has more than 150 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Total volume of shares traded on the bourses today was lower by 72.50% to 399,151 compared with 22-day average volume of 1,451,266.

Shares of the company gained Rs 3.2, or 0.64%, to trade at Rs 506.60. The total volume of shares traded was 13,613 at the BSE (9.46 a.m., Friday).